GS is drifting lower against a backdrop where the Street collectively sees 10% more value in the stock than the market is currently pricing, making the absence of a catalyst — not the absence of conviction — the dominant tension heading into October.
The price action has turned modestly softer since last week's report. GS closed Tuesday at $1,034.41, down 1.8% on the week and now about 2% below where it ended July. That puts the stock roughly $107 below the mean analyst target of $1,141.65 — a gap that has proven persistent. The $22 recovery from the early-August low near $1,018 has stalled, and GS is again underperforming its closest peer: MS fell less than 1% on the week, while EVR dropped more sharply, off 5.2%, providing some relative comfort for GS holders but no real momentum catalyst.
The lending market offers no meaningful signal here. Short interest has continued its multi-week unwind, easing another 1.5% on the week to land at roughly 2.0% of free float — a level that simply does not sustain a bear thesis on its own. Borrow is essentially free at 0.26% annualised, down sharply from 0.38% earlier in the month, and availability is vast, with over 154 million shares available in the lending pool. There is no squeeze dynamic, no cost-of-carry pressure, and nothing in the short book that reads as a directional bet of note. Options tell a similarly unexciting story: the put/call ratio at 0.86 is fractionally below its 20-day average of 0.88, putting it well within the range it has held all summer. Neither side of the options market is expressing unusual conviction.
The Street's view is where things get more interesting. The consensus is broadly constructive but internally divided on price. Most of the target revisions filed in mid-July — after GS printed a record Q2 with a 10% single-day surge — landed in the $1,130–$1,245 range from firms including Barclays, Citigroup, and Evercore ISI. BofA stands out at $1,300, the highest known target in the set. JP Morgan, by contrast, kept its target at $955 — below the current price — reflecting a more cautious read on normalisation in capital markets revenues. UBS, the most recent mover (target raised to $1,150 on August 3 while maintaining Neutral), sits in the middle. The factor scorecard reinforces the constructive tilt: EPS momentum ranks in the 94th percentile over 30 days and 93rd over 90 days, EPS surprise at the 88th percentile, and the analyst recommendation differential — a measure of how much the Street has shifted bullish relative to history — ranks in the 91st percentile. The one weak spot is forward earnings growth, which ranks only in the 22nd percentile, pointing to a firm that has delivered impressively but where the growth trajectory from here is less clear.
The bull case rests on GS's franchise strength in M&A advisory and its expanding asset and wealth management revenues reducing exposure to more volatile trading income. The bear case centres on continued reliance on capital markets activity and the risk that any macro slowdown disproportionately hits advisory volumes. Neither argument has changed materially since Q2 results. The ORTEX short score at 32.3 has been essentially flat for two weeks, reinforcing a picture of low conviction in either direction.
The next scheduled earnings event is October 13. Between now and then, the primary watchpoint is whether GS can sustain price levels above $1,030 as the Street's consensus target continues to inch higher — or whether the gap to consensus simply reflects a valuation the market has decided not to close until the next fundamental update arrives.
See the live data behind this article on ORTEX.
Open GS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
